Timetable: Initial (full) marketing authorisation application assessment
Timetable: Initial (full) marketing authorisation application assessment
Timetable: Initial (full) marketing authorisation application assessment
Pharmacovigilance Risk Assessment Committee (PRAC): 13-16 January 2025, European Medicines Agency, Amsterdam, the Netherlands, from 13 January 2025 to 16 January 2025
Agenda of the CVMP meeting 14-15 January 2025
Orphan designation: Davunetide Treatment of activity-dependent neuroprotective protein (ADNP) syndrome, 13/12/2024 Positive
Orphan designation: roginolisib Treatment of uveal melanoma, 13/12/2024 Positive
Human medicines European public assessment report (EPAR): Pepaxti, melphalan flufenamide, Date of authorisation: 17/08/2022, Revision: 5, Status: Authorised
Procedure for the preparation of European Union herbal monographs and European Union list entries and appointment of HMPC rapporteurs and peer-reviewers
Minutes - PDCO minutes of the 12-15 November 2024 meeting
Orphan designation: Vosoritide Treatment of hypochondroplasia, 13/12/2024 Positive
Orphan designation: votoplam Treatment of Huntington's disease, 13/12/2024 Positive